The Use of Artificial Intelligence for the Prediction of Recurrence After Resection of Colorectal Liver Metastases
Recruiting
Observational Study
Colorectal Liver Metastasis (CRLM)
Liver Resection
Hepatectomy
Liver Ablation
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,000 (estimated)
- Sponsor
- Francesco De Cobelli · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Colorectal cancer is the third most common cancer worldwide and the fourth most common cause of cancer-related death. Survival is primarily determined by stage of disease and the presence of metastases. The combination of chemotherapy and liver resection remains the treatment option with the highest survival benefit for patients with liver metastases from colorectal cancer, with surgery still bein…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Pathologically confirmed diagnosis (at final pathology) of liver metastases from colon or rectal adenocarcinoma
* \> 6 months of follow-up
* no other concomitant neoplastic disease
Exclusion Criteria:
* All subjects receiving hepatic resection but not fulfilling the inclusio…
Contacts